Literature DB >> 4157335

Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and -resistant staphylococci.

J N Minuth, T M Holmes, D M Musher.   

Abstract

Tetracycline, doxycycline, and minocycline were evaluated for their antibacterial activity against methicillin-susceptible and -resistant isolates of Staphylococcus. At clinically achievable levels both doxycycline and minocycline were more active than tetracycline against methicillin-susceptible organisms. Tetracycline and doxycycline had no activity against methicillin-resistant staphylococci, whereas minocycline at 2 mug/ml inhibited six of 13 strains and, at 3 mug/ml, 10 of 13 strains.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4157335      PMCID： PMC444661          DOI： 10.1128/AAC.6.4.411

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations.

Authors:  F F Barrett; R F McGehee; M Finland
Journal:  N Engl J Med       Date:  1968-08-29       Impact factor: 91.245

2.  Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro.

Authors:  N H Steigbigel; C W Reed; M Finland
Journal:  Am J Med Sci       Date:  1968-03       Impact factor: 2.378

3.  In vitro activity of minocycline, a new tetracycline.

Authors:  J Fedorko; S Katz; H Allnoch
Journal:  Am J Med Sci       Date:  1968-04       Impact factor: 2.378

4.  Growing clinical significance of methcillin-resistant Staphylococcus aureus.

Authors:  E J Benner; F H Kayser
Journal:  Lancet       Date:  1968-10-05       Impact factor: 79.321

5.  Absorption and excretion of five tetracycline analogues in normal young men.

Authors:  N H Steigbigel; C W Reed; M Finland
Journal:  Am J Med Sci       Date:  1968-05       Impact factor: 2.378

6.  The mode of action of antibiotics on gram-negative bacilli.

Authors:  V Lorian
Journal:  Arch Intern Med       Date:  1971-10

7.  An outbreak of methicillin-resistant Staphylococcus aureus infection. Observations in hospital and nursing home.

Authors:  R D O'Toole; W L Drew; B J Dahlgren; H N Beaty
Journal:  JAMA       Date:  1970-07-13       Impact factor: 56.272

8.  Bacteriological evaluation of minocycline, a new tetracycline.

Authors:  J Klastersky; D Daneau
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

9.  Efficacy of standard disc-diffusion test as applied to susceptibility of Staphylococcus aureus to tetracycline and minocycline.

Authors:  M C Bach; S H Zinner; C Wilcox; M Finland
Journal:  J Lab Clin Med       Date:  1972-02

10.  Clinical pharmacologic studies with minocycline.

Authors:  B Bernard; E J Yin; H J Simon
Journal:  J Clin Pharmacol New Drugs       Date:  1971 Sep-Oct
View more
  14 in total

Review 1.  Antibacterial drugs today. I.

Authors:  A P Ball; J A Gray; J M Murdoch
Journal:  Drugs       Date:  1975       Impact factor: 9.546

Review 2.  Community-associated meticillin-resistant Staphylococcus aureus.

Authors:  Frank R DeLeo; Michael Otto; Barry N Kreiswirth; Henry F Chambers
Journal:  Lancet       Date:  2010-03-05       Impact factor: 79.321

3.  Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis.

Authors:  Rodrigo Peixoto Campos; Marcelo Mazza do Nascimento; Domingos Candiota Chula; Miguel Carlos Riella
Journal:  J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 10.121

4.  Minocycline resistance in Staphylococcus aureus: effect on phage susceptibility.

Authors:  S Schaefler; W Francois; C L Ruby
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

5.  Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jörg J Ruhe; Anupama Menon
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.

Authors:  I Raad; R Hachem; H Hanna; E Girgawy; K Rolston; E Whimbey; R Husni; G Bodey
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1975       Impact factor: 9.546

8.  Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus.

Authors:  E Yourassowsky; M P van der Linden; M J Lismont; F Crokaert
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

9.  Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.

Authors:  D P Nicolau; C D Freeman; C H Nightingale; C J Coe; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Antibiotics and prevention of microbial colonization of catheters.

Authors:  I Raad; R Darouiche; R Hachem; M Sacilowski; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.